Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cozzi, P. J.
Right arrow Articles by Hall, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cozzi, P. J.
Right arrow Articles by Hall, J. B.
(Chest. 1999;116:1159-1162.)
© 1999 American College of Chest Physicians

Cyclophosphamide in the Treatment of Pulmonary Diseases*

Survey of Use, Training, and Practitioner Knowledge Base

Phillip J. Cozzi, MD and Jesse B. Hall, MD, FCCP

* From the Critical Care Section (Dr. Cozzi), Elmhurst Memorial Hospital, Elmhurst, IL; and the Section of Pulmonary and Critical Care Medicine (Dr. Hall), Department of Medicine, University of Chicago, Pritzker School of Medicine, Chicago, IL.

Objective: To assess pulmonologists’ use, training in the use, and knowledge base of the drug cyclophosphamide.

Design: Survey through questionnaire. Testing of knowledge base before and after instructional conference.

Participants and methods: Pulmonologists (94 attendings, 31 fellows), selected randomly at the 1996 and 1997 annual meetings of The American Thoracic Society, completed surveys of their use and training in the use of cyclophosphamide. Thirty-five attending at the 1998 meeting completed a test of knowledge base of the drug. Members of the pulmonary teaching service at The University of Chicago Hospitals completed the test before and after a case-based conference designed to educate pulmonologists in the use of the drug.

Results: Forty-three percent of the attending pulmonologists and 55% of the fellows were currently using the drug in the management of their patients; 77% of the attending pulmonologists had prescribed the drug in the past. Nonmalignant diseases for which the drug was prescribed included usual interstitial pneumonitis/desquamative interstitial pneumonitis, vasculitis, collagen vascular disease, constrictive bronchiolitis, sarcoid, and Goodpasture’s disease. Sixty-eight percent of attending pulmonologists and 81% of fellows had no training in the drug’s use. Of the attending pulmonologists who made use of the drug, 64% were prescribing and managing its use themselves. Of those who prescribed and managed the drug’s use themselves, 65% had had no training in its use. Of those fellows who prescribed and managed the drug’s use themselves, 73% had had no training in the drug’s use. On knowledge-based testing, the average correct score was 30 ± 10%. With an educational conference, average pre- and post-test scores rose from 40 ± 10% to 80 ± 10% (p < 0.001).

Conclusion: Cyclophosphamide had been used by the vast majority of pulmonologists, either currently or in the past, for a wide variety of lung diseases. Its use is commonly managed by physicians who have no specific training relevant to this agent. Practitioner knowledge base of the drug is poor, and case-based conferences in fellowship may be an effective means of imparting information concerning this drug.

Key Words: cyclophosphamide • survey • training • knowledge base






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.